latest news releases from the newsroom
EQUITIES Magazine Interviews John Chambers, President of Rodman & Renshaw's Acumen BioFin
LOS ANGELES, Nov. 5, 2007 (PRIME NEWSWIRE) -- The November issue of EQUITIES is now available at newsstands nationwide and at bookstores such as Barnes and Noble, B.Dalton, and Books-A-Million. In it, the biotech market is examined by John Chambers, head of Acumen BioFin-the life-science division of the investment bank Rodman & Renshaw (Nasdaq:RODM).
NYSE Euronext CEO Jean-Francois Theodore Interviewed in EQUITIES Magazine
LOS ANGELES, Nov. 5, 2007 (PRIME NEWSWIRE) -- EQUITIES magazine proudly announces the inclusion of a one-on-one interview with Jean-Francois Theodore in the November 2007 issue. As the deputy CEO and director of NYSE Euronext (NYSE:NYX), Theodore is the second in command at the world's largest stock-market group.
Avigen Presents At the 37th Annual Meeting of the Society for Neuroscience
ALAMEDA, Calif., Nov. 4, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapies for the treatment of chronic neurological conditions, today announced the company presented data from a Phase I study of one of its leading pipeline products, AV650 (tolperisone HCl), at the 37th annual meeting of the Society for Neuroscience (SfN) on November 4, 2007 at the San Diego Convention Center in San Diego, California. This Phase I data showed AV650 to be well tolerated with no evidence of sedation.